Mackay Shields LLC trimmed its position in Johnson & Johnson (NYSE:JNJ) by 4.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 658,768 shares of the company’s stock after selling 30,951 shares during the quarter. Mackay Shields LLC’s holdings in Johnson & Johnson were worth $85,231,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Premier Asset Management LLC increased its holdings in shares of Johnson & Johnson by 6.1% during the third quarter. Premier Asset Management LLC now owns 4,349 shares of the company’s stock worth $563,000 after purchasing an additional 249 shares during the period. BW Gestao de Investimentos Ltda. bought a new position in shares of Johnson & Johnson during the third quarter worth approximately $2,588,000. Franklin Parlapiano Turner & Welch LLC increased its holdings in shares of Johnson & Johnson by 3.3% during the third quarter. Franklin Parlapiano Turner & Welch LLC now owns 41,632 shares of the company’s stock worth $5,386,000 after purchasing an additional 1,334 shares during the period. Synovus Financial Corp increased its holdings in shares of Johnson & Johnson by 1.1% during the third quarter. Synovus Financial Corp now owns 307,807 shares of the company’s stock worth $39,810,000 after purchasing an additional 3,356 shares during the period. Finally, Independence Advisors LLC increased its holdings in shares of Johnson & Johnson by 216.1% during the third quarter. Independence Advisors LLC now owns 19,785 shares of the company’s stock worth $2,560,000 after purchasing an additional 13,526 shares during the period. 72.25% of the stock is currently owned by institutional investors.
Shares of NYSE JNJ traded up $1.57 during trading hours on Friday, hitting $133.00. 4,856,974 shares of the stock were exchanged, compared to its average volume of 7,224,392. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.00 and a current ratio of 1.26. The company has a market cap of $343.25 billion, a PE ratio of 16.26, a price-to-earnings-growth ratio of 2.20 and a beta of 0.69. The company’s fifty day simple moving average is $130.83 and its two-hundred day simple moving average is $134.05. Johnson & Johnson has a 1-year low of $121.00 and a 1-year high of $148.99.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.12 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.00 by $0.12. The business had revenue of $20.73 billion for the quarter, compared to analyst estimates of $20.14 billion. Johnson & Johnson had a net margin of 21.09% and a return on equity of 39.81%. The firm’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter last year, the business posted $2.05 EPS. As a group, sell-side analysts expect that Johnson & Johnson will post 8.65 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Tuesday, November 26th will be given a dividend of $0.95 per share. The ex-dividend date is Monday, November 25th. This represents a $3.80 annualized dividend and a dividend yield of 2.86%. Johnson & Johnson’s dividend payout ratio is 46.45%.
JNJ has been the topic of several recent research reports. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Zacks Investment Research raised shares of Johnson & Johnson from a “sell” rating to a “hold” rating and set a $142.00 target price on the stock in a report on Thursday, October 17th. Raymond James lowered their target price on shares of Johnson & Johnson from $146.00 to $145.00 and set an “outperform” rating on the stock in a report on Monday, October 14th. Atlantic Securities raised shares of Johnson & Johnson from an “underweight” rating to a “neutral” rating in a report on Wednesday, October 16th. Finally, Credit Suisse Group increased their price target on shares of Johnson & Johnson from $158.00 to $163.00 in a research report on Thursday, October 24th. Six investment analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $151.64.
Johnson & Johnson Profile
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Further Reading: Bid-Ask Spread
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.